BMJ Publishing Group Ltd and European League Against Rheumatism
-
Publisher Of
- FRI0196 TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 2 COHORTS OF AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL 2019
- SAT0395 RESPONSIVENESS AND CLINICAL TRIAL DISCRIMINATION OF SWOLLEN AND TENDER JOINT COUNTS FOR THE MEASUREMENT OF MSK DISEASE ACTIVITY IN PSORIATIC ARTHRITIS 2019
- AB0071 Effects of chondroitin sulphate and glucosamine on inflammatory cytokines in macrophages 2018
- AB0072 Evaluation of anti-inflammatory effects of naproxen sodium on human osteoarthritis synovial cells 2018
- OP0200 Characteristics and outcomes of prospectively reported pregnancies exposed to certolizumab pegol from a safety database 2018
- SAT0241 Patients’ perspective on the efficacy and risks of glucocorticoids in ra – an initiative under the gloria project 2018
- THU0242 Pregnancy outcomes and disease activity in women with axial spondyloarthritis: a systematic literature review 2018
- FRI0157 Fertility in women with rheumatoid arthritis compared to healthy controls 2017
- FRI0179 Minimal to no transfer of certolizumab pegol into breast milk: results from cradle, a prospective, postmarketing, multicenter, pharmacokinetic study 2017
- SAT0119 Pregnancy outcomes in women with and without rheumatoid arthritis 2017
- SAT0466 Pregnancy in women with psoriatic arthritis: pregnancy outcomes and changes in disease activity 2017
- THU0044 Chondroitin sulphate inhibits monocyte chemoattractant protein-1 release from 3T3L1 adipocytes: a new treatment opportunity for obesity-related metabolic syndromes? 2017
- THU0677 Outcome measurement instruments for safety in rheumatology: a scoping review of available instruments to inform the omeract safety working group 2017